Profil
Martin Kristofferson is currently Chief Operating Officer at EQL Pharma AB since 2022.
Formerly, Mr. Kristofferson was Sourcing Director at BioGaia AB and Chief Marketing Officer at LEO Pharma AB. Mr. Kristofferson graduated from the University of Linköping.
Postes actifs de Martin Kristofferson
| Sociétés | Poste | Début |
|---|---|---|
| EQL PHARMA AB | Directeur des opérations | 17/08/2022 |
Anciens postes connus de Martin Kristofferson
| Sociétés | Poste | Fin |
|---|---|---|
LEO Pharma AB
LEO Pharma AB LEO Pharma AB is an independent, Swedish research-driven pharmaceutical company specializing in dermatology, with a history spanning over 100 years from its origins in Copenhagen. The company is based in Malmö, Sweden. The company employs approximately 5,200 people worldwide and serves 92 million patients across 130 countries. LEO Pharma is majority-owned by the independent LEO Foundation, with Nordic Capital holding a minority stake. Its Nordic hub operates in Sweden, with about 25 employees focused on sales, marketing, medical affairs, and supply. The company’s product portfolio includes dermatological and thrombotic treatments. | Sales & Marketing | - |
| BIOGAIA AB | Corporate Officer/Principal | - |
Formation de Martin Kristofferson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
BioGaia AB
BioGaia AB Pharmaceuticals: OtherHealth Technology Develops health care products such as foods with healthy additives and provides pharmaceutical research services | Health Technology |
University of Linköping
University of Linköping Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EQL Pharma AB
EQL Pharma AB Pharmaceuticals: GenericHealth Technology Manufactures and distributes generic and specialty pharmaceutical products | Health Technology |
LEO Pharma AB
LEO Pharma AB LEO Pharma AB is an independent, Swedish research-driven pharmaceutical company specializing in dermatology, with a history spanning over 100 years from its origins in Copenhagen. The company is based in Malmö, Sweden. The company employs approximately 5,200 people worldwide and serves 92 million patients across 130 countries. LEO Pharma is majority-owned by the independent LEO Foundation, with Nordic Capital holding a minority stake. Its Nordic hub operates in Sweden, with about 25 employees focused on sales, marketing, medical affairs, and supply. The company’s product portfolio includes dermatological and thrombotic treatments. |
















